NASDAQ:NVCR - Novocure Stock Price, Forecast & News

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Novocure Ltd (NASDAQ:NVCR) announced its quarterly earnings results on Thursday, October, 31st. The medical equipment provider reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.07. The medical equipment provider earned $92.06 million during the quarter, compared to analysts' expectations of $87.12 million. Novocure had a negative net margin of 8.43% and a negative return on equity of 18.45%. The business's revenue for the quarter was up 42.2% on a year-over-year basis. During the same period last year, the business earned ($0.13) earnings per share. View Novocure's Earnings History.

Novocure is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Novocure.

Novocure will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Novocure updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $351.3-351.3 million, compared to the consensus revenue estimate of $347.69 million.

6 Wall Street analysts have issued 1-year price targets for Novocure's shares. Their forecasts range from $50.00 to $97.00. On average, they expect Novocure's stock price to reach $80.33 in the next twelve months. This suggests that the stock has a possible downside of 16.4%. View Analyst Price Targets for Novocure.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure.

Press coverage about NVCR stock has trended negative on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novocure earned a news impact score of -2.0 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the immediate future. View News Stories for Novocure.

Novocure saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,110,000 shares, an increase of 5.4% from the January 15th total of 3,900,000 shares. Based on an average daily trading volume, of 906,500 shares, the days-to-cover ratio is presently 4.5 days. Currently, 5.2% of the shares of the stock are short sold. View Novocure's Current Options Chain.

Some companies that are related to Novocure include FRESENIUS SE &/S (FSNUY), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), ICU Medical (ICUI), Nevro (NVRO) and NuVasive (NUVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), NVIDIA (NVDA) and Roper Technologies (ROP).

Novocure's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (12.31%), Baillie Gifford & Co. (8.09%), Capital World Investors (5.09%), Renaissance Technologies LLC (2.27%), State Street Corp (1.69%) and Capital International Investors (1.40%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Institutional Ownership Trends for Novocure.

NVCR stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Mitsubishi UFJ Trust & Banking Corp, Goldman Sachs Group Inc., Renaissance Technologies LLC, UBS Asset Management Americas Inc., Nicholas Investment Partners LP, Jacobs Levy Equity Management Inc. and Citigroup Inc.. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and William F Doyle. View Insider Buying and Selling for Novocure.

NVCR stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Invus Financial Advisors LLC, FMR LLC, Fiera Capital Corp, Panagora Asset Management Inc., State Street Corp, Pictet Asset Management Ltd. and California Public Employees Retirement System. View Insider Buying and Selling for Novocure.

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVCR stock can currently be purchased for approximately $96.13.

Novocure has a market capitalization of $9.51 billion and generates $248.07 million in revenue each year. The medical equipment provider earns $-63,560,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. View Additional Information About Novocure.

The official website for Novocure is http://www.novocure.com/.

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]